These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35878189)

  • 101. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia.
    Stong BC; DelGaudio JM; Hapner ER; Johns MM
    Arch Otolaryngol Head Neck Surg; 2005 Sep; 131(9):793-5. PubMed ID: 16172357
    [TBL] [Abstract][Full Text] [Related]  

  • 102. [Indications for botulinum toxin in laryngectomy].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E; Cohen M
    Rev Laryngol Otol Rhinol (Bord); 1993; 114(4):281-7. PubMed ID: 8029549
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
    Hogikyan ND; Wodchis WP; Spak C; Kileny PR
    J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
    [TBL] [Abstract][Full Text] [Related]  

  • 104. The prevalence and clinical features of spasmodic dysphonia: A review of epidemiological surveys conducted in Japan.
    Hyodo M; Hisa Y; Nishizawa N; Omori K; Shiromoto O; Yumoto E; Sanuki T; Nagao A; Hirose K; Kobayashi T; Asano K; Sakaguchi M
    Auris Nasus Larynx; 2021 Apr; 48(2):179-184. PubMed ID: 32861505
    [TBL] [Abstract][Full Text] [Related]  

  • 105. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial.
    Kohli N; Lerner M; Rashty J; Kirke D; Stewart T; Blitzer A
    Am J Otolaryngol; 2022; 43(6):103613. PubMed ID: 36055061
    [TBL] [Abstract][Full Text] [Related]  

  • 106. The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment.
    Morzaria S; Damrose EJ
    J Laryngol Otol; 2011 Jul; 125(7):714-8. PubMed ID: 21524329
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Electromyographic assessment of spasmodic dysphonia patients prior to botulinum toxin injection.
    Rodriquez AA; Ford CN; Bless DM; Harmon RL
    Electromyogr Clin Neurophysiol; 1994; 34(7):403-7. PubMed ID: 7859668
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Botulinum toxin for the treatment of spasmodic dysphonia.
    Gibbs SR; Blitzer A
    Otolaryngol Clin North Am; 2000 Aug; 33(4):879-94. PubMed ID: 10918666
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Retropharyngeal hematoma following botulinum toxin injection for abductor spasmodic dysphonia.
    Koh J; Raghav S; Baxter M
    Ear Nose Throat J; 2017 Dec; 96(12):E45-E46. PubMed ID: 29236283
    [No Abstract]   [Full Text] [Related]  

  • 110. Adductor spasmodic dysphonia: case reports with acoustic analysis following botulinum toxin injection and acupuncture.
    Crevier-Buchman L; Laccourreye O; Papon JF; Nurit D; Brasnu D
    J Voice; 1997 Jun; 11(2):232-7. PubMed ID: 9181547
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Durability of Titanium Implants Following Type II Thyroplasty for Adductor Type Spasmodic Dysphonia.
    Toya Y; Hiroshiba S
    Laryngoscope; 2023 Nov; 133(11):3028-3033. PubMed ID: 37070643
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Laryngeal Sensory Symptoms in Spasmodic Dysphonia.
    Vanderaa V; Vinney LA
    J Voice; 2023 Mar; 37(2):302.e1-302.e12. PubMed ID: 33485747
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia.
    Yeung W; Richards AL; Novakovic D
    Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548741
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Spasmodic dysphonia: introductory phonetic analyses.
    Reid EW; Nobriga CV
    Clin Linguist Phon; 2023 Oct; 37(10):883-898. PubMed ID: 35818753
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Hemodynamic Changes Associated With Transcervical Laryngeal Injection of Botulinum Toxin.
    Hernandez BO; Nagatsuka M; Wright SC; Marcellino AJ; Lovin BD; Walker FO; Madden LL
    J Voice; 2023 May; 37(3):452-455. PubMed ID: 33541763
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Significance of age and sex in botulinum neurotoxin dosing for adductor spasmodic dysphonia.
    Heyes R; Adler CH; Zhang N; Lott DG; Bansberg SF
    World J Otorhinolaryngol Head Neck Surg; 2023 Jun; 9(2):168-173. PubMed ID: 37383332
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Safety and Effectiveness of OnabotulinumtoxinA in Patients with Laryngeal Dystonia: Final Report of a 52-Week, Multicenter Postmarketing Surveillance Study.
    Iimura S; Nose Y; Tabata K; Oda K; Yamashita Y; Takahashi N; Kawano Y
    Toxins (Basel); 2023 Sep; 15(9):. PubMed ID: 37755979
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Comparison of the efficacy and adverse effects of unilateral or bilateral botulinum toxin injections for adductor spasmodic dysphonia: a systematic review and meta-analysis.
    Liu Y; Chen F; Liang F; Wang C; Chen D; Zhou J; Zhang L; Xiao X; He R; Tang L; Tian L; Zhou L
    Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1357-1369. PubMed ID: 38095707
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Guidelines for the Use of Botulinum Toxin in Otolaryngology From the Korean Society of Laryngology, Phoniatrics and Logopedics Guideline Task Force.
    Ban MJ; Ryu CH; Woo JH; Lee YC; Lee DK; Kwon M; Hong YT; Lee GJ; Byeon HK; Choi SH; Lee SW
    Clin Exp Otorhinolaryngol; 2023 Nov; 16(4):291-307. PubMed ID: 37905325
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update.
    Hyodo M; Hirose K; Nagao A; Nakahira M; Kobayashi T
    Toxins (Basel); 2022 Jul; 14(7):. PubMed ID: 35878189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.